Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07656168

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07656168
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07656168. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2028-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure
Acronym
PHOENIX
Condition
ESRD (End-Stage Renal Disease)
Condition
Maintenance Hemodialysis
Intervention (Device)
pHA130 Hemoadsorption Cartridge
Intervention (Device)
High-flux Hemodialyzer
Lead sponsor
China-Japan Friendship Hospital (class: other)
Collaborator
Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine (class: other)

Record details

Record id
cardio:ct-nct07656168
Content hash
b314d31260c7127d2c2e84a6d7a481cbff15c07285d0919c0e06513f8781764c